CNS Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Operating expenses | $16.0M | $14.9M | $18.9M | $15.3M | $14.5M |
| Cash from operations | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Capital expenditure | $18,175 | $4,188 | $3,901 | $4,422 | $5,748 |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M |
Shares outstanding 1.5M · Free float 49.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.